18 November 2023
: Case report 
Oligometastatic Melanoma Treated by Metastasectomy in Combination with Immune Checkpoint and BRAF Inhibitors: A Case Series
Unusual or unexpected effect of treatment
John P. Palmer1ADEF*, Arief A. Suriawinata2BDE, Shaofeng Yan2BDE, Darcy A. Kerr2BDE, Muhammad Z. Afzal1ABCE, Keisuke Shirai1ADEFDOI: 10.12659/AJCR.938537
Am J Case Rep 2023; 24:e938537
Figure 9. Case 3: (A) Excisional biopsy of the subcutaneous nodule showing a hypercellular lesion centered in the subcutis with peripheral infiltration of fat (hematoxylin and eosin [H&E], original magnification ×7). (B) The tumor cells show nuclear pleomorphism and prominent mitotic activity (H&E, ×200). Immunohistochemical staining confirms metastatic melanoma with (C) diffuse SOX10 (immunohistochemistry [IHC], ×200) and (D) MiTF positivity (IHC, ×200). (E) A subsequent small bowel metastasis presents as an irregular tumor nodule involving the mucosa and submucosa (H&E, ×5). (F) Higher magnification demonstrates similar features, with nuclear pleomorphism and mitotic activity (H&E, ×400).